CatalystMarker
← board

OABI

distress 5/10 · elevated risk
$2.08-2%today-24% from 52w high
omniab.com89 employeesFounded 2012EmeryVille, CABiotechnology
Revenue
$14M
Liquidity
$29M
Runway
1.1 yrs
Shares 1y
+18%

Price & events

+0.3% over 6M
$1.36$2.04$2.72Jan 26Apr 26Jul 265.7M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
+1.8%
1W
-10.9%
1M
+33.1%
3M
+5.9%
6M
-3.4%
1Y
-56.1%
2Y
5Y
-78.7%
All

Overview

Market Cap
$300.96M
Volume
16.82K
52 Week Range
$1.36 – $2.72
Total Shares
144.97M
Float Shares
113.85M
Short %
3.60%
% Held by Insiders
15.33%
% Held by Institutions
50.97%
RVOL
0.03x
Beta
1.17

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 144,972,579 · 0 offerings/1y · 1 PIPEs
  • 2025-09-19EFFECTshelf_effective
  • 2025-09-12S-3shelf_registration
  • 2025-08-258-Kprivate_placement
  • 2024-11-14SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2025-08-07RBC CapitalOutperform
  • 2025-05-12BenchmarkBuy
  • 2025-03-27RBC CapitalOutperform
  • 2025-03-20BenchmarkBuy
  • 2025-03-19HC Wainwright & Co.Buy
  • 2024-11-14BenchmarkBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.